800 West Hill Street, Suite 100, Carolinas Pathology Group,
Charlotte, North Carolina, 80501
Tanzania
Research Article
Comparison of Molecular Testing Methods for Detecting BRAF V600 Mutations in Melanoma Specimens with Challenging Attributes
Author(s): John Longshore, Sherene Banawan, Heather Amidon, Heather Todd, Jeffrey Fu, Mari Christensen, Julie Tsai, Grant Hillman, Shannon Walter, Felice Shieh, Edward Lipford, Guili Zhang, Abha Sharma and John F PalmaJohn Longshore, Sherene Banawan, Heather Amidon, Heather Todd, Jeffrey Fu, Mari Christensen, Julie Tsai, Grant Hillman, Shannon Walter, Felice Shieh, Edward Lipford, Guili Zhang, Abha Sharma and John F Palma
Introduction: To ensure the appropriate assignment of vemurafenib to patients with unresectable or metastatic melanoma, accurate detection of activating BRAF mutations is now a clinical imperative. However, the performance of commercially available test kits on challenging samples is unknown.
Methods: 126 formalin-fixed, paraffin-embedded melanoma samples were selected for challenging attributes, such as small sample size, that might affect test kit performance. The Qiagen BRAF RGQ PCR version 2 (RGQv2) test kit, intended for research use only, and the FDA-approved companion diagnostic cobas 4800 BRAF V600 Mutation Test were compared for their ability to detect the V600E mutation in challenging samples, using a single 5 μm unstained slide.
Results: of the 126 specimens, three samples were invalid by the RGQv2 test.. Read More»
DOI:
10.4172/2155-9929.1000215
Molecular Biomarkers & Diagnosis received 2054 citations as per Google Scholar report